AZD4320 Dual BCL-2/BCL-XL Inhibitor: Handling & Assay Protocol
AZD4320 Dual BCL-2/BCL-XL Inhibitor: Handling & Assay Protocol
AZD4320 is a potent, dual BH3-mimetic small molecule that inhibits both BCL-2 and BCL-XL anti-apoptotic proteins, making it a valuable research tool for studying programmed cell death and evaluating therapeutic strategies in hematologic and solid tumor models.
- Target
- BCL-2 and BCL-XL (dual inhibitor)
- Mechanism
- BH3 mimetic; displaces pro-apoptotic BH3-only proteins from BCL-2/BCL-XL, triggering mitochondrial apoptosis
- Recommended Solvent
- DMSO (dimethyl sulfoxide) for stock solution preparation
- Storage Conditions
- Store desiccated at -20 °C; protect from light and moisture
- Research Application
- Apoptosis induction, cancer cell viability assays, BCL-2 family protein interaction studies
- SKU
- A607867
Materials and Stock Solution Preparation
AZD4320 (SKU: A607867) is supplied as a solid powder. Before use, prepare a concentrated stock solution to simplify accurate dosing in downstream assays.
- Weigh the compound: Allow the vial to equilibrate to room temperature (approximately 15–30 minutes) before opening to prevent condensation on the powder.
- Dissolve in DMSO: Reconstitute AZD4320 in anhydrous DMSO to a recommended stock concentration of 10 mM. Vortex gently and, if necessary, warm briefly to 37 °C to aid dissolution. Do not use aqueous buffers directly, as solubility is limited in water.
- Aliquot and store: Divide the stock solution into single-use aliquots in microcentrifuge tubes. Seal tightly, label with date and concentration, and store at -20 °C protected from light. Avoid repeated freeze-thaw cycles (<3 cycles recommended).
- Working solution: Dilute stock in cell culture medium or assay buffer immediately before use. The final DMSO concentration in assay wells should not exceed 0.1% (v/v) to minimise solvent cytotoxicity. Prepare a vehicle (DMSO-only) control at the same final solvent concentration.
Note: Verify compound purity and concentration by UV absorbance or HPLC if critical quantitation is required. All specific solubility values should be confirmed against the Certificate of Analysis supplied with each lot.
Cell Culture and Treatment Protocol
AZD4320 is suitable for use in a range of adherent and suspension cancer cell lines. The following protocol provides a general framework; optimise conditions for your specific cell model.
Cell seeding
- Seed cells at an appropriate density in 96-well (viability assays) or 6-well (Western blot, flow cytometry) plates 24 hours prior to treatment to allow attachment and equilibration.
- Maintain cells in recommended complete growth medium at 37 °C, 5% CO₂.
Compound treatment
- Prepare a dilution series of AZD4320 working solution (e.g., 0.001–10 µM) in pre-warmed complete medium.
- Remove existing medium from wells and replace with treatment medium containing AZD4320 or vehicle control.
- Incubate cells for the desired duration. Typical treatment windows range from 6–72 hours depending on the endpoint; shorter incubations (6–24 h) are suitable for early apoptosis markers, longer incubations (48–72 h) for viability readouts.
Positive and negative controls
- Negative control: Cells treated with equivalent volume of DMSO vehicle.
- Positive control: A known apoptosis inducer appropriate for the cell line (e.g., staurosporine at 1 µM for 4 h).
Note: Specific effective concentrations of AZD4320 vary by cell line and BCL-2/BCL-XL expression levels. Dose–response experiments are strongly recommended before committing to a fixed concentration.
Apoptosis and Cell Viability Readout Methods
Multiple orthogonal assays can be used to quantify AZD4320-mediated apoptosis and cytotoxicity. Select the most appropriate method(s) for your experimental question.
Cell viability (ATP-based luminescence)
ATP-based luminescent reagents (e.g., CellTiter-Glo) provide a rapid, quantitative measure of metabolically active cells. Add reagent per manufacturer instructions after compound incubation, measure luminescence, and calculate percentage viability relative to vehicle control. Determine IC₅₀ by non-linear regression curve fitting.
Annexin V / Propidium Iodide (PI) flow cytometry
This assay discriminates between viable, early apoptotic, late apoptotic, and necrotic populations. After treatment, collect both floating and adherent cells, wash with cold PBS, and stain with Annexin V–FITC and PI according to the kit protocol. Acquire samples on a flow cytometer within 1 hour of staining.
Caspase-3/7 activation assay
Caspase-3 and -7 are effector caspases activated during intrinsic apoptosis. Use a luminogenic caspase-3/7 substrate reagent or immunofluorescence with an anti-cleaved caspase-3 antibody to confirm apoptotic signalling downstream of BCL-2/BCL-XL inhibition.
Western blotting
Assess BCL-2 and BCL-XL protein expression, cytochrome c release, and cleavage of PARP or caspase-9 as mechanistic markers confirming on-target activity. Harvest cells in RIPA buffer supplemented with protease and phosphatase inhibitors.
Safety, Waste Disposal, and Troubleshooting
Safety: AZD4320 is a research-use-only (RUO) compound. As with all potent bioactive small molecules, handle with appropriate personal protective equipment (PPE): laboratory coat, nitrile gloves, and eye protection. Work in a ventilated area or chemical fume hood when handling DMSO stock solutions. Consult the Safety Data Sheet (SDS) supplied with the product before use.
Waste disposal: Dispose of AZD4320-containing solutions and contaminated materials in accordance with local institutional and regulatory guidelines for hazardous chemical waste. Do not pour concentrated solutions down the drain.
Troubleshooting guide
| Problem | Likely Cause | Suggested Action |
|---|---|---|
| No apoptosis observed | Cell line has low BCL-2/BCL-XL dependence; insufficient compound concentration; short incubation | Confirm target expression by Western blot; increase concentration or incubation time; use a BCL-2-dependent positive control line |
| Excessive non-specific toxicity | DMSO concentration too high; compound degradation | Reduce DMSO to ≤0.1%; check stock integrity; prepare fresh working solution |
| Poor compound solubility | Aqueous dilution too rapid; concentration too high | Warm stock to 37 °C before dilution; do not exceed recommended working concentration |
| High well-to-well variability | Uneven cell seeding; pipetting error | Seed cells carefully; use multichannel pipette; increase replicates to n≥3 |
Frequently asked questions
What is the recommended solvent and stock concentration for AZD4320?
AZD4320 should be dissolved in anhydrous DMSO to prepare a stock solution, with a typical recommended concentration of 10 mM. Aqueous buffers are not suitable for direct dissolution due to limited water solubility. Aliquots should be stored at -20 °C and protected from light.
Which cancer cell lines are most suitable for testing AZD4320 activity?
Cell lines with high expression of BCL-2 and/or BCL-XL, such as certain hematologic malignancy-derived lines, are expected to show greatest sensitivity to AZD4320. It is advisable to confirm target protein expression by Western blot before experimental use. Specific validated cell lines should be confirmed against published literature or the product datasheet.
How should I confirm that AZD4320 is acting on-target in my assay?
On-target activity can be confirmed by demonstrating BCL-2- and BCL-XL-dependent apoptosis induction. Mechanistic confirmation includes detecting cytochrome c release from mitochondria, activation of caspase-9 and caspase-3/7, and cleavage of PARP by Western blot or immunofluorescence. Including a BH3 profiling step prior to treatment can also predict cellular dependence on BCL-2/BCL-XL.
What is the maximum acceptable DMSO concentration in cell-based assays using AZD4320?
The final DMSO concentration in assay wells should generally not exceed 0.1% (v/v) to avoid solvent-related cytotoxicity confounding results. Always include a vehicle control (DMSO at the same final concentration) alongside AZD4320-treated wells to account for any residual solvent effects.
How should unused AZD4320 stock solution be stored to maintain stability?
Store aliquoted AZD4320 DMSO stock solutions at -20 °C in tightly sealed tubes, protected from light and moisture. Avoid repeated freeze-thaw cycles; it is recommended to limit freeze-thaw to fewer than three cycles. The solid powder should also be stored desiccated at -20 °C. Always allow the vial to reach room temperature before opening to prevent moisture condensation.
References
- Tse C, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research. 2008. [AZD4320 is a related dual BCL-2/BCL-XL inhibitor; specific AZD4320 primary references require verification.]
- Merino D, et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science Translational Medicine. 2017. [Cited as background on BCL-2 family inhibition strategy; not specific to AZD4320.]
- Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Current Opinion in Genetics & Development. 2011. [General BCL-2 family biology background.]
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证（带存储）